Doxorubicin Market Size, Share, Trends, Business Growth, Report & Industry Forecast 2023-2028
The global doxorubicin market size reached US$ 1.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 1.7 Billion by 2028, exhibiting a growth rate (CAGR) of 6.04% during 2023-2028.
Doxorubicin, an essential chemotherapy drug, plays a vital role in combating several forms of cancer, such as breast cancer, lung cancer, ovarian cancer, bladder cancer, and specific types of leukemia and lymphoma. This medication falls under the anthracycline class of drugs, derived from a natural compound synthesized by specific bacteria. Its primary mechanism of action involves impeding the proliferation and metastasis of cancer cells within the body. Typically, doxorubicin is administered intravenously by healthcare professionals in a controlled hospital or clinic environment.
Doxorubicin Market Trends and Drivers:
The global demand for doxorubicin remains robust, driven by several factors. The escalating incidence of cancer, coupled with a growing elderly population that is particularly susceptible to these diseases, is a key catalyst behind the increased utilization of doxorubicin. Furthermore, the surge in demand for minimally invasive (MI) surgical procedures, favored by both healthcare professionals and patients due to their numerous advantages, is fueling market expansion. Additionally, the heightened awareness surrounding cancer, its symptoms, diagnostic techniques, and the wide availability of treatment options, is positively influencing the market. The proliferation of online pharmacies has also made accessing doxorubicin more convenient for patients, thereby contributing to market growth. Moreover, the pharmaceutical industry's intensified focus on conducting clinical trials further strengthens the market's upward trajectory.
Get a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/doxorubicin-market/requestsample
Global Doxorubicin Market 2023-2028 Analysis and Segmentation:
Competitive Landscape:
The
competitive landscape of the market has been studied in the report with the
detailed profiles of the key players operating in the market.
Accord
Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc.,
Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings
Co. Ltd., Novartis AG and Pfizer Inc.
The report
has segmented the market on the basis of region, application and distribution
channel.
Breakup by
Application:
·
Breast Cancer
·
Ovarian Cancer
· Multiple
Myeloma
· Kaposi
Sarcoma
· Leukemia
· Bone
Sarcoma
·
Endometrial
Cancer
·
Others
Breakup by
Distribution Channel:
·
Hospital and
Retail Pharmacies
·
Online Stores
·
Others
Breakup by
Region:
·
North America
o
United States
o
Canada
·
Asia-Pacific
o
China
o
Japan
o
India
o
South Korea
o
Australia
o
Indonesia
o
Others
·
Europe
o
Germany
o
France
o
United Kingdom
o
Italy
o
Spain
o
Russia
o
Others
·
Latin America
o
Brazil
o
Mexico
o
Others
·
Middle East and
Africa
Ask Analyst for Customization and Explore Full Report with TOC &
List of Figure:
https://www.imarcgroup.com/request?type=report&id=5677&flag=C
If you want
latest primary and secondary data (2023-2028) with Cost Module, Business
Strategy, Distribution Channel, etc. Click request free sample report,
published report will be delivered to you in PDF format via email within 24 to
48 hours of receiving full payment.
Key highlights of the report:
- Market
Performance (2017-2022)
- Market
Outlook (2023- 2028)
- Porter’s
Five Forces Analysis
- Market
Drivers and Success Factors
- SWOT
Analysis
- Value
Chain
- Comprehensive
Mapping of the Competitive Landscape
If you need
specific information that is not currently within the scope of the report, we
can provide it to you as a part of the customization.
About Us:
IMARC Group
is a leading market research company that offers management strategy and market
research worldwide. We partner with clients in all sectors and regions to
identify their highest-value opportunities, address their most critical
challenges, and transform their businesses.
IMARC’s
information products include major market, scientific, economic and
technological developments for business leaders in pharmaceutical, industrial,
and high technology organizations. Market forecasts and industry analysis for
biotechnology, advanced materials, pharmaceuticals, food and beverage, travel
and tourism, nanotechnology and novel processing methods are at the top of the
company’s expertise.
Contact Us:
IMARC Services Private Limited.
United States
134 N 4th
St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia:
+91-120-433-0800, +91-120-433-0800
Comments
Post a Comment